Number of the records: 1  

Perinatal Hypoxic-Ischemic Damage: Review of the Current Treatment Possibilities

  1. 1.
    SYSNO ASEP0538469
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitlePerinatal Hypoxic-Ischemic Damage: Review of the Current Treatment Possibilities
    Author(s) Frajewicki, A. (CZ)
    Laštůvka, Z. (CZ)
    Borbélyová, V. (SK)
    Khan, S. (CZ)
    Jandová, K. (CZ)
    Janišová, K. (CZ)
    Otáhal, Jakub (FGU-C) RID, ORCID, SAI
    Mysliveček, J. (CZ)
    Riljak, V. (CZ)
    Source TitlePhysiological Research. - : Fyziologický ústav AV ČR, v. v. i. - ISSN 0862-8408
    Roč. 69, Suppl.3 (2020), S379-S401
    Number of pages23 s.
    Languageeng - English
    CountryCZ - Czech Republic
    Keywordshypoxia ; hypoxic-ischemic encephalopathy ; immature brain ; treatment
    Subject RIVFH - Neurology
    OECD categoryNeurosciences (including psychophysiology
    Method of publishingOpen access
    Institutional supportFGU-C - RVO:67985823
    UT WOS000610191500004
    EID SCOPUS85100228214
    DOI10.33549/physiolres.934595
    AnnotationNeonatal hypoxic-ischemic encephalopathy is a disorder with heterogeneous manifestation due to asphyxia during perinatal period. It affects approximately 3-12 children per 1000 live births and cause death of 1 million neonates worldwide per year. Besides, motor disabilities, seizures, impaired muscle tone and epilepsy are few of the consequences of hypoxic-ischemic encephalopathy. Despite an extensive research effort regarding various treatment strategies, therapeutic hypothermia with intensive care unit supportive treatment remains the only approved method for neonates who have suffered from moderate to severe hypoxicischemic encephalopathy. However, these protocols are only partially effective given that many infants still suffer from severe brain damage. Thus, further research to systematically test promising neuroprotective treatments in combination with hypothermia is essential. In this review, we discussed the pathophysiology of hypoxic-ischemic encephalopathy and delved into different promising treatment modalities, such as melatonin and erythropoietin. However, preclinical studies and clinical trials are still needed to further elucidate the mechanisms of action of these modalities.
    WorkplaceInstitute of Physiology
    ContactLucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
    Year of Publishing2021
    Electronic addresshttp://www.biomed.cas.cz/physiolres/pdf/2020/69_S379.pdf
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.